Vestmark Advisory Solutions Inc. Sells 79,481 Shares of Haleon PLC Sponsored ADR $HLN

Vestmark Advisory Solutions Inc. cut its holdings in Haleon PLC Sponsored ADR (NYSE:HLN) by 53.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 68,712 shares of the company’s stock after selling 79,481 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Haleon were worth $616,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in HLN. JTC Employer Solutions Trustee Ltd boosted its holdings in shares of Haleon by 120.7% during the 3rd quarter. JTC Employer Solutions Trustee Ltd now owns 712,229 shares of the company’s stock worth $6,392,000 after buying an additional 389,467 shares in the last quarter. Arlington Partners LLC lifted its position in shares of Haleon by 128.0% during the 3rd quarter. Arlington Partners LLC now owns 508,886 shares of the company’s stock valued at $4,565,000 after acquiring an additional 285,692 shares during the period. Archford Capital Strategies LLC bought a new position in Haleon during the third quarter worth $2,149,000. New York State Common Retirement Fund acquired a new stake in Haleon in the second quarter worth $3,964,000. Finally, Acadian Asset Management LLC grew its holdings in Haleon by 3,031.5% in the second quarter. Acadian Asset Management LLC now owns 5,384,661 shares of the company’s stock worth $55,813,000 after purchasing an additional 5,212,711 shares during the period. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Trading Up 3.2%

Shares of HLN stock opened at $10.77 on Friday. Haleon PLC Sponsored ADR has a 52-week low of $8.71 and a 52-week high of $11.42. The company has a 50-day simple moving average of $10.43 and a two-hundred day simple moving average of $9.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.63 and a current ratio of 0.87. The company has a market capitalization of $47.96 billion, a price-to-earnings ratio of 27.62 and a beta of 0.19.

Haleon Dividend Announcement

The firm also recently announced a dividend, which will be paid on Thursday, May 14th. Stockholders of record on Friday, April 10th will be paid a dividend of $0.1307 per share. This represents a dividend yield of 251.0%. The ex-dividend date is Friday, April 10th. Haleon’s payout ratio is presently 28.21%.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research note on Thursday, January 22nd. Jefferies Financial Group reiterated a “buy” rating on shares of Haleon in a report on Tuesday, January 20th. Deutsche Bank Aktiengesellschaft downgraded Haleon from a “hold” rating to a “sell” rating in a report on Monday, January 12th. HSBC upgraded Haleon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 21st. Finally, Morgan Stanley reissued an “overweight” rating on shares of Haleon in a research report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $12.33.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.